Skip to main content
Biocartis Group NV logo

Biocartis Group NV — Investor Relations & Filings

Ticker · BCART ISIN · BE0974281132 LEI · 549300J4HOJL5KG8HY54 BR Manufacturing
Open in API
Filings indexed 636 across all filing types
Latest filing 2022-04-21 Earnings Release
Country BE Belgium
Listing BR BCART

About Biocartis Group NV

https://www.biocartis.com/en

Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.

Recent filings

Filing Released Lang Actions
220420 Q1 2022 Business Update_ENG_FINAL.pdf
Earnings Release Classification · 100% confidence The document is titled "Biocartis Reports Results of First Quarter of 2022" and contains detailed financial highlights (Product revenue, Gross margin, Operating cash burn) and an outlook for the full year 2022, specifically referencing Q1 2022 performance. This structure is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results, often in the form of a press release. It is not a comprehensive, formal regulatory filing like a 10-K or a full Interim Report (IR), but rather the summary announcement. The document length (10,310 chars) is substantial, suggesting it is more than just a brief announcement of a report (RPA/RNS). It contains the core results and management commentary, fitting the definition of an Earnings Release (ER). Q1 2022
2022-04-21 English
220420 Q1 2022 Business Update_NL_FINAL.pdf
Earnings Release Classification · 100% confidence The document is titled "Biocartis rapporteert resultaten eerste kwartaal 2022" (Biocartis reports first quarter 2022 results) and contains detailed financial figures (revenue, gross margin, cash burn) specifically for Q1 2022, along with forward-looking guidance for the full year 2022. It also includes a financial calendar mentioning the 'H1 2022 resultaten' (H1 2022 results) and 'Q3 2022 Business Update'. The content is a comprehensive summary of period performance, which aligns perfectly with the definition of an Interim/Quarterly Report (IR). It is not just a brief announcement of results (ER), nor is it the full annual report (10-K). Q1 2022
2022-04-21 Dutch
Commissarisverslag - Statutaire Jaarrekening FY 2021.pdf
Audit Report / Information Classification · 98% confidence The document is titled 'Verslag van de commissaris aan de algemene vergadering over het boekjaar afgesloten op 31 december 2021 - Jaarrekening' (Commissioner's report to the general meeting on the financial year ended December 31, 2021 - Annual Accounts). It contains an 'Oordeel zonder voorbehoud' (Unqualified opinion) and extensive sections detailing the 'Basis voor het oordeel zonder voorbehoud' (Basis for the unqualified opinion), 'Kernpunten van de controle' (Key audit matters), and 'Verantwoordelijkheden van de commissaris voor de controle van de jaarrekening' (Responsibilities of the commissioner for the audit of the annual accounts). This structure is characteristic of an independent auditor's report accompanying the financial statements. Since the text explicitly refers to the 'Jaarrekening' (Annual Accounts) and is the formal report from the statutory auditor ('commissaris'), it aligns best with the Audit Report / Information category (AR), which covers standalone audit reports, rather than the full Annual Report (10-K) which typically includes management discussion and the full financial statements prepared by the company. FY 2021
2022-04-12 Dutch
Jaarverslag FY 2021.pdf
Annual Report Classification · 100% confidence The document is titled 'JAARVERSLAG 2021' (Annual Report 2021) for Biocartis Group NV. It contains comprehensive sections including a message from the CEO, strategy, sustainability, corporate governance, and a detailed financial report (Financieel Verslag 2021) covering the period from January 1, 2021, to December 31, 2021. As it is a full annual report containing financial statements and management analysis, it is classified as a 10-K (Annual Report). FY 2021
2022-04-12 Dutch
Deelnemingsformulier.pdf
AGM Information Classification · 98% confidence The document is explicitly titled "DEELNEMINGSFORMULIER VOOR HOUDERS VAN EFFECTEN" / "ATTENDANCE FORM FOR SECURITIES HOLDERS" for the "Gewone algemene aandeelhoudersvergadering" / "Annual shareholders' meeting". This form is used by shareholders to register their intent to attend the meeting. This material is directly related to the preparation and logistics of the Annual General Meeting (AGM). While it is not the final voting result (DVA) or the proxy solicitation material itself (PSI), it is a core component of the AGM process. Given the options, AGM-R (AGM Information) is the most appropriate classification as it covers presentations and materials shared during the AGM, and this form is essential preparatory material for that event.
2022-04-12 Dutch
Commissarisverslag - Geconsolideerde Jaarrekening FY 2021.pdf
Audit Report / Information Classification · 99% confidence The document is explicitly titled "Verslag van de commissaris aan de algemene vergadering over het boekjaar afgesloten op 31 december 2021 - Geconsolideerde jaarrekening" (Commissioner's Report to the General Meeting on the financial year ended December 31, 2021 - Consolidated Financial Statements). It contains an unqualified opinion ("Oordeel zonder voorbehoud") on the consolidated financial statements prepared according to IFRS, and details the scope of the statutory audit performed by Deloitte. This structure is characteristic of an Audit Report, which includes the auditor's opinion on the financial statements, rather than the full Annual Report (10-K) itself, which is typically filed with the SEC and contains much more comprehensive business descriptions and management discussion. Since it is a standalone report detailing the audit results and principles applied, the most appropriate classification is Audit Report / Information (AR). FY 2021
2022-04-12 Dutch

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.